Drug Trial Radar · NCT07045311
JS207 Combination Therapy in Triple-negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Sep 17, 2025
Primary completion
Mar 22, 2028
Study completion Mar 22, 2029
Sponsor
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.
Conditions
- Triple-negative Breast Cancer
Interventions
JS207 in combination with 9MW2821Drug
JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), 9MW2821 will be administered intravenously at a dose of 1.25 m.g/kg (D1 and D8, Q3W)
JS207 in combination with Albumin paclitaxelDrug
JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), Albumin paclitaxel will be administered intravenously at a dose of 125 mg/m2 (D1 and D8, Q3W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 2years
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Not yet recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China · Recruiting
Guangdong women and children's hospital and health institute
Guangzhou, Guangdong, China · Not yet recruiting
Affiliated Hospital of Hebei University
Baoding, Hebei, China · Recruiting
Harbin Medical University Affiliated Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Harbin Medical University Affiliated Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhangzhou, Henan, China · Recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Recruiting
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Nanchang People'S Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Jilin University First Hospital
Changchun, Jilin, China · Recruiting
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Liaoning Cancer Hospital&Institute
Shenyang, Liaoning, China · Recruiting
Ceneral Hosipital of Ningxia Medical University
Yinchuan, Ningxia, China · Not yet recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xian, Shanxi, China · Recruiting
Xi'an International Medical Center Hospital
Xian, Shanxi, China · Recruiting
Affiliated Tumor Hospital of Xinjiang Medical University
Ürümqi, Xinjiang Uygur Autonomous Region, China · Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.